Advertisement

Sodium Butyrate Enhances Intestinal Riboflavin Uptake via Induction of Expression of Riboflavin Transporter-3 (RFVT3)

  • Veedamali S. Subramanian
  • Subrata Sabui
  • Christopher W. Heskett
  • Hamid M. Said
Original Article

Abstract

Background

Uptake of riboflavin (RF) by intestinal epithelial cells occurs via a specific carrier-mediated process that involves the apically localized RF transporter-3 (RFVT3). Previous studies have shown that sodium butyrate (NaB) affects intestinal uptake of other substrates and expression of their membrane transporters, but its effect on intestinal uptake of RF and expression of RFVT3 has not been examined.

Aims

To investigate the effect of NaB on intestinal RF uptake process and expression of the RFVT3.

Methods

Two experimental models were used in this study: Human-derived intestinal epithelial Caco-2 cells and ex vivo mouse colonoids. 3H-RF uptake assay, Western blot, RT-qPCR, and chromatin immunoprecipitation assay were performed.

Results

Treating Caco-2 cells with NaB led to a significant increase in carrier-mediated RF uptake. This increase was associated with a significant induction in the level of expression of the hRFVT3 protein, mRNA, and heterogenous nuclear RNA (hnRNA). Similarly, treating mouse colonoids with NaB led to a marked increase in the level of expression of the mRFVT3 protein, mRNA, and hnRNA. NaB did not affect hRFVT3 mRNA stability, rather it caused significant epigenetic changes (histone modifications) in the SLC52A3 gene where an increase in H3Ac and a reduction in H3K27me3 levels were observed in the NaB-treated Caco-2 cells compared to untreated controls.

Conclusion

These findings demonstrate that NaB up-regulates intestinal RF uptake and that the effect appears to be mediated, at least in part, at the level of transcription of the SLC52A3 gene and may involve epigenetic mechanism(s).

Keywords

Riboflavin RFVT3 Intestine Sodium butyrate Colonoids 

Notes

Acknowledgments

This study was supported by Grants from the Department of Veterans Affairs and the NIH (Grants DK107474 to VSS, and DK58057, DK56057, and AA018071 to HMS).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Cooperman JM, Lopez R. Riboflavin. In: Machlin LJ, ed. Handbook of Vitamins: Nutritional, Biochemical and Clinical Aspects. New York: Dekker; 1984:299–327.Google Scholar
  2. 2.
    Tu BP, Ho-Schleyer SC, Travers KJ, Weissman JS. Biochemical basis of oxidative protein folding in the endoplasmic reticulum. Science. 2000;290:1571–1574.CrossRefGoogle Scholar
  3. 3.
    Sanches SC, Ramalho LN, Mendes-Bras M, et al. (vitamin B-2) reduces hepatocellular injury following liver ischaemia and reperfusion in mice. Food Chem Toxicol. 2014;67:65–71.CrossRefGoogle Scholar
  4. 4.
    Liu D, Zempleni J. Low activity of LSD1 elicits a pro-inflammatory gene expression profile in riboflavin-deficient human T Lymphoma Jurkat cells. Genes Nutr. 2014;9:422.CrossRefGoogle Scholar
  5. 5.
    Brestoff JR, Artis D. Commensal bacteria at the interface of host metabolism and the immune system. Nat Immunol. 2013;14:676–684.CrossRefGoogle Scholar
  6. 6.
    Mazur-Bialy AI, Buchala B, Plytycz B. Riboflavin deprivation inhibits macrophage viability and activity—a study on the RAW 264.7 cell line. Br J Nutr. 2013;110:509–514.CrossRefGoogle Scholar
  7. 7.
    Schramm M, Wiegmann K, Schramm S, et al. Riboflavin (vitamin B2) deficiency impairs NADPH oxidase 2 (Nox2) priming and defense against Listeria monocytogenes. Eur J Immunol. 2014;44:728–741.CrossRefGoogle Scholar
  8. 8.
    Fernandez-Banares F, Abad-Lacruz A, Xiol X, et al. Vitamin status in patients with inflammatory bowel disease. Am J Gastroenterol. 1989;84:744–748.PubMedGoogle Scholar
  9. 9.
    Rosenthal WS, Adham NF, Lopez R, Cooperman JM. Riboflavin deficiency in complicated chronic alcoholism. Am J Clin Nutr. 1973;26:858–860.CrossRefGoogle Scholar
  10. 10.
    Kodentsova VM, Vrzhesinskaia OA, Trofimenko EV, et al. The vitamin status of children with diabetes mellitus. Vopr Med Khim. 1994;40:45–48.PubMedGoogle Scholar
  11. 11.
    Bosch AM, Abeling NG, Ijlst L, et al. Brown–Vialetto–Van Laere and Fazio Londe syndrome is associated with a riboflavin transporter defect mimicking mild MADD: a new inborn error of metabolism with potential treatment. J Inherit Metab Dis. 2011;34:159–164.CrossRefGoogle Scholar
  12. 12.
    Green P, Wiseman M, Crow YJ, et al. Brown–Vialetto–Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in C20orf54. Am J Hum Genet. 2010;86:485–489.CrossRefGoogle Scholar
  13. 13.
    Ho G, Yonezawa A, Masuda S, et al. Maternal riboflavin deficiency, resulting in transient neonatal-onset glutaric gciduria type 2, 1s caused by a microdeletion in the riboflavin transporter gene GPR172B. Hum Mut. 2011;32:E1976–E1984.CrossRefGoogle Scholar
  14. 14.
    Johnson JO, Gibbs JR, Megarbane A, et al. Exome sequencing reveals riboflavin transporter mutations as a cause of motor neuron disease. Brain. 2012;185:2875–2882.CrossRefGoogle Scholar
  15. 15.
    Iinuma S. Synthesis of riboflavin by intestinal bacteria. J Vitaminol. 1955;1:6–13. (Kyoto).CrossRefGoogle Scholar
  16. 16.
    Kasper H. Vitamin absorption in the colon. Am J Protocol. 1970;21:341–345.Google Scholar
  17. 17.
    Said HM, Arianas P. Transport of riboflavin in human intestinal brush border membrane vesicles. Gastroenterology. 1991;100:82–88.CrossRefGoogle Scholar
  18. 18.
    Sorrell MF, Frank O, Thompson AD, Aquino A, Baker H. Absorption of vitamins from the large intestine. Nutr Rep Int. 1971;3:143–148.Google Scholar
  19. 19.
    Middleton HM. Uptake of riboflavin by rat intestinal mucosa in vitro. J Nutr. 1985;120:588–593.CrossRefGoogle Scholar
  20. 20.
    Said HM, Ma TY. Regulation of riboflavine intestinal uptake by Caco-2 cells. Am J Physiol. 1994;266:G15–G21.PubMedGoogle Scholar
  21. 21.
    Said HM, Mohammadkhani R. Uptake of riboflavin across the brush border membrane of rat intestine: regulation by dietary vitamin levels. Gastroenterology. 1993;105:1294–1298.CrossRefGoogle Scholar
  22. 22.
    Yamamoto S, Inoue K, Ohta KY, et al. Identification and functional characterization of rat riboflavin transporter 2. J Biochem. 2009;145:437–443.CrossRefGoogle Scholar
  23. 23.
    Yao Y, Yonezawa A, Yoshimatsu H, et al. Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brain. J Nutr. 2010;140:1220–1226.CrossRefGoogle Scholar
  24. 24.
    Yonezawa A, Masuda S, Katsura T, Inui K. Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. Am J Physiol Cell Physiol. 2008;295:C632–C641.CrossRefGoogle Scholar
  25. 25.
    Yonezawa A, Inui K. Novel riboflavin transporter family RFVT/SLC52: identification, functional characterization and genetic diseases of RFVT/SLC52. Mol Aspects Med. 2013;34:693–701.CrossRefGoogle Scholar
  26. 26.
    Subramanian VS, Subramanya SB, Rapp L, et al. Differential expression of human riboflavin transporters -1, -2, and -3 in polarized epithelia: a key role for hRFT-2 in intestinal riboflavin uptake. Biochim Biophys Acta. 2011;1808:3016–3021.CrossRefGoogle Scholar
  27. 27.
    Subramanian VS, Lambrecht N, Lytle C, Said HM. Conditional (intestinal-specific) knockout of the riboflavin transporter-3 (RFVT-3) impairs riboflavin absorption. Am J Physiol Gastrointest Liver Physiol. 2016;310:G285–G293.CrossRefGoogle Scholar
  28. 28.
    Bosch AM, Stroek K, Abeling NG, et al. The Brown–Vialetto–Van Laere and Fazio Londe syndrome revised: natural history, genetics, treatment and future perspectives. Orphanet J Rare Dis.. 2012;7:83.CrossRefGoogle Scholar
  29. 29.
    Cummings JH. Short chain fatty acids in the human colon. Gut. 1981;22:763–779.CrossRefGoogle Scholar
  30. 30.
    Ganapathy V, Thangaraju M, Prasad PD, Martin PM, Singh N. Transporters and receptors for short-chain fatty acids as the molecular link between colonic bacteria and the host. Curr Opin Pharmacol. 2013;13:869–874.CrossRefGoogle Scholar
  31. 31.
    Cummings JH, Macfarlane GT. The control and consequences of bacterial fermentation in the human colon. J Appl Bacteriol. 1991;70:443–459.CrossRefGoogle Scholar
  32. 32.
    Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut. 1987;28:1221–1227.CrossRefGoogle Scholar
  33. 33.
    Wrong O, Metcalfe-gibson A, Morrison RB, Ng ST, Howard AV. In vivo dialysis of faeces as a method of stool analysis. i. technique and results in normal subjects. Clin Sci. 1965;28:357–375.PubMedGoogle Scholar
  34. 34.
    Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut. 1980;21:793–798.CrossRefGoogle Scholar
  35. 35.
    Dalmasso G, Nguyen HT, Yan Y, et al. Butyrate transcriptionally enhances peptide transporter PepT1 expression and activity. PLoS ONE. 2008;3:e2476.CrossRefGoogle Scholar
  36. 36.
    Musch MW, Bookstein C, Xie Y, Sellin JH, Chang EB. SCFA increase intestinal Na absorption by induction of NHE3 in rat colon and human intestinal C2/bbe cells. Am J Physiol Gastrointest Liver Physiol. 2001;280:G687–G693.CrossRefGoogle Scholar
  37. 37.
    Xu H, McCoy A, Li J, Zhao Y, Ghishan FK. Sodium butyrate stimulates NHE8 expression via its role on activating NHE8 basal promoter activity. Am J Physiol Gastrointest Liver Physiol. 2015;309:G500–G505.CrossRefGoogle Scholar
  38. 38.
    Mangian HF, Tappenden KA. Butyrate increases GLUT2 mRNA abundance by initiating transcription in Caco2-BBe cells. JPEN J Parenter Enteral Nutr. 2009;33:607–617.CrossRefGoogle Scholar
  39. 39.
    Zeissig S, Fromm A, Mankertz J, et al. Butyrate induces intestinal sodium absorption via Sp3-mediated transcriptional up-regulation of epithelial sodium channels. Gastroenterology. 2007;132:236–248.CrossRefGoogle Scholar
  40. 40.
    Subramanian VS, Ghosal A, Kapadia R, Nabokina SM, Said HM. Molecular mechanisms mediating the adaptive regulation of intestinal riboflavin uptake process. PLoS ONE. 2015;10:e0131698.CrossRefGoogle Scholar
  41. 41.
    Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology. 2011;141:1762–1772.CrossRefGoogle Scholar
  42. 42.
    Tsuruta T, Saito S, Osaki Y, et al. Organoids as an ex vivo model for studying the serotonin system in the murine small intestine and colon epithelium. Biochem Biophys Res Commun. 2016;474:161–167.CrossRefGoogle Scholar
  43. 43.
    Anandam KY, Srinivasan P, Subramanian VS, Said HM. Molecular mechanisms involved in the adaptive regulation of the colonic thiamin pyrophosphate uptake process. Am J Physiol Cell Physiol. 2017;313:C655–C663.CrossRefGoogle Scholar
  44. 44.
    Livek KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta DeltaC (T)) method. Methods. 2001;25:402–408.CrossRefGoogle Scholar
  45. 45.
    Lakhan R, Subramanian VS, Said HM. Role of MicroRNA-423-5p in posttranscriptional regulation of the intestinal riboflavin transporter-3. Am J Physiol Gastrointest Liver Physiol. 2017;313:G589–G598.CrossRefGoogle Scholar
  46. 46.
    Subramanian VS, Sabui S, Teafatiller T, Bohl JA, Said HM. Structure/functional aspects of the human riboflavin transporter-3 (SLC52A3): role of the predicted glycosylation and substrate-interacting sites. Am J Physiol Cell Physiol. 2017;313:C228–C238.CrossRefGoogle Scholar
  47. 47.
    Subramanian VS, Srinivasan P, Said HM. Uptake of ascorbic acid by pancreatic acinar cells is negatively impacted by chronic alcohol exposure. Am J Physiol Cell Physiol. 2016;311:C129–C135.CrossRefGoogle Scholar
  48. 48.
    Reidling JC, Nabokina SM, Said HM. Molecular mechanisms involved in the adaptive regulation of human intestinal biotin uptake: a study of the hSMVT system. Am J Physiol Gastrointest Liver Physiol. 2007;292:G275–G281.CrossRefGoogle Scholar
  49. 49.
    Li G, Reinberg D. Chromatin higher-order structures and gene regulation. Curr Opin Genet Dev. 2011;21:175–186.CrossRefGoogle Scholar
  50. 50.
    Vidali G, Boffa LC, Bradbury EM, Allfrey VG. Butyrate suppression of histone deacetylation leads to accumulation of multiacetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences. Proc Natl Acad Sci USA. 1978;75:2239–2243.CrossRefGoogle Scholar
  51. 51.
    Bogliotti YS, Ross PJ. Mechanisms of histone H3 lysine 27 trimethylation remodeling during early mammalian development. Epigenetics. 2012;7:976–981.CrossRefGoogle Scholar
  52. 52.
    Sabui S, Subramanian VS, Kapadia R, Said HM. Adaptive regulation of pancreatic acinar mitochondrial thiamin pyrophosphate uptake process: possible involvement of epigenetic mechanism(s). Am J Physiol Gastrointest Liver Physiol. 2017;313:G448–G455.CrossRefGoogle Scholar
  53. 53.
    Ghosal A, Sabui S, Said HM. Identification and characterization of the minimal 5′-regulatory region of the human riboflavin transporter-3 (SLC52A3) in intestinal epithelial cells. Am J Physiol Cell Physiol. 2015;308:C189–C196.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Veedamali S. Subramanian
    • 1
    • 2
  • Subrata Sabui
    • 1
    • 2
  • Christopher W. Heskett
    • 1
    • 2
  • Hamid M. Said
    • 1
    • 2
  1. 1.Departments of Medicine and Physiology/BiophysicsUniversity of CaliforniaIrvineUSA
  2. 2.VA Medical CenterLong BeachUSA

Personalised recommendations